Literature DB >> 25651257

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.

Jan-Willem Alffenaar, Tawanda Gumbo, Rob Aarnoutse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25651257     DOI： 10.1056/NEJMc1414718

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

2.  Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Authors:  Jotam G Pasipanodya; Wynand Smythe; Corinne S Merle; Piero L Olliaro; Devyani Deshpande; Gesham Magombedze; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

3.  Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Shashikant Srivastava; Devyani Deshpande; Marianne E Visser; Emmanuel Chigutsa; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Authors:  Shashikant Srivastava; Devyani Deshpande; Gesham Magombedze; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

5.  Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.

Authors:  Marc Weiner; Jon Gelfond; Teresa L Johnson-Pais; Melissa Engle; Charles A Peloquin; John L Johnson; Erin E Sizemore; William R Mac Kenzie
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 6.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

7.  Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Authors:  Anushka Naidoo; Maxwell Chirehwa; Helen McIlleron; Kogieleum Naidoo; Sabiha Essack; Nonhlanhla Yende-Zuma; Eddy Kimba-Phongi; John Adamson; Katya Govender; Nesri Padayatchi; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.758

Review 8.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.